Jaguar Health für Investierte und Interessierte Forum: Community User: Bsjunge

Oder es kommt anders 😅 Bei der Aktie weiß man nie 🤪

Das stimmt, die haben kaum noch etwas auszuleihen (shares) noch 6000 Stück, hsben sich grad nochmal ca. 90k ausgeliehen

das ausleihen ist viel viel viel zu Günstig (vielleicht sollte man das shorten verbieten) 😃

weiss nicht ob ich nachkaufen sollte weil ek ist 0,21wenn ich nachkaufe kurs grad günstig ,kann ja sein die Bude macht ein Rs dann hab ich noch mehr verloren.Guter Rat ist nun gefragt,Was meint ihr finger weg oder nachkaufen?

Dann müssen wir uns wohl bis Q3 gedulden

https://finance.yahoo.com/news/napo-pharmaceuticals-jaguar-health-family-124500876.html

Nurses play a vital role in providing integrated supportive care to cancer survivors to meet various physical, psychological, and social support needs," added Conte. "Jaguar and Napo acknowledge the rigors of both short-term and perpetual treatment and do not believe any cancer therapy-related side effect, whether it is extreme fatigue, debilitating diarrhea, oral mucositis, hair loss, chronic pain, or others, should ever be viewed as ‘acceptable' or ‘tolerable.' We live in the age targeted therapies, and thanks to these amazing drugs cancer patients are living longer - 5, 10, 20 years. Targeted therapies often lead to more severe side effects, however, and patients want to live, not just survive."

Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024 Company to feature "Make Cancer Less Shitty" patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the Oncology Nursing Society (ONS) Congress taking place April 24-28, 2024 in Washington, DC. "We look forward to driving awareness among the oncology nursing community at this event about Jaguar's expanding focus on cancer supportive care," said Lisa Conte, Jaguar's president and CEO. "We are expanding our footprint beyond HIV-related supportive care to include cancer-related supportive care, and our recent in-licensing of the oral mucositis product Gelclair ® is a first building block. Results are forthcoming for our pivotal Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea, an indication we also refer to as chemotherapy-induced overactive bowel (CIOB) - which includes symptoms such as unpredictable and/or chronic debilitating diarrhea and GI urgency." Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Also called "chemo mouth," oral mucositis has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network (NCCN) task force. 1 An FDA-approved prescription product, Gelclair is a protective gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. Unlike other products for oral mucositis, it is not a numbing agent and does not sting the mouth.

*gelcair

Und gelclair ist ja nicht gleichzusetzen mit p3 Ergebnis ☝🏼

Im Nachhinein ist mir auch klar warum sie nicht an der ASCO die Ergebnisse präsentieren, da sie zum Zeitpunkt der Anmeldung wahrscheinlich noch gar nicht die Ergebnisse hatten und nicht wussten, wie diese ausfallen würden.

Trotzdem mega

Vom 16.4.24

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-licenses-fda-approved-oral-mucositis-product-us